Ex) Article Title, Author, Keywords
Ex) Article Title, Author, Keywords
2017; 9(1): 36-40
Published online September 30, 2017
Copyright © Korean Society for Pharmacoepidemiology and Risk Management.
Sang Chul Lee,MD1,2, Nasil Kong,MD1, Jinyoung Choi,MD1, Sunyoung Kim,MD1, Kyung Hee Park,MD1,2 and Jung-Won Park, MD, PhD1,2
이상철1,2, 공나실1, 최진영1, 김선영1, 박경희1,2, 박중원1,2
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Tuberculosis remains a major public health problem worldwide. Fist-line antitubercular agents such as isoniazid, rifampin, ethambutol and pyrazinamide can considered as initial therapy. But, hypersensitivity reaction to antituberculosis drugs can occur in 4-5% of the general population which usually leads to cessation of and switching of therapy. Drug desensitization can be effective alternative to patient with drug hypersensitivity. Herein, the authors introduce a 32-year-old female in whom multiple drug hypersensitivity developed 2 weeks after the initiation of first-line antituberculosis agents (isoniazid, 300 mg; rifampin, 600 mg; pyrazinamide, 1,500 mg; and ethambutol, 800 mg). We tried one by one to resume antituberculosis treatment. After successful desensitization of all 4 first-line antitubercular agents, she’s now on the therapy without any complications. (JPERM 2017;9:-40): Desensitization, Immunologic; Drug-Related Side Effects and Adverse Reactions; Tuberculosis; Antitubercular Agents
Keywords Desensitization, Immunologic, Drug-Related Side Effects and Adverse Reactions, Tuberculosis, Antitubercular Agents
